GVAX Plus Checkpoint Blockade in Neuroblastoma

Summary

This research clinical trial is studying the creation and administration of GVAX, an irradiated GM-CSF secreting, autologous neuroblastoma cell vaccine (GVAX) in combination with nivolumab and ipilimumab as a possible treatment for neuroblastoma. The names of the study drugs involved in this study are: * GVAX Vaccine, an immunotherapy developed from surgically removed tumor tissue * Nivolumab * Ipilimumab

Timeline

Start

2020-01-29

Primary completion

2024-01-27

Completion

2024-02-29

Outcome

Outcome not reported

Stopped: “Manufacturing issues”

Drugs

Indications